A combinatorial approach for achieving CNS-selective RNAi
Nucleic Acids Research · 2024
DOI: 10.1093/nar/gkae100 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, 2024. Verfasst von Chantal M Ferguson und 12 weiteren Autor:innen. Beteiligte Einrichtung: RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA, 01605, USA. Hauptthemen laut MEDLINE: Central Nervous System, RNA Interference. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alzheimer's Drug Discovery Foundation, NIA NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
RNA interference (RNAi) is an endogenous process that can be harnessed using chemically modified small interfering RNAs (siRNAs) to potently modulate gene expression in many tissues. The route of administration and chemical architecture are the primary drivers of oligonucleotide tissue distribution, including siRNAs. Independently of the nature and type, oligonucleotides are eliminated from the body through clearance tissues, where their unintended accumulation may result in undesired gene modulation. Divalent siRNAs (di-siRNAs) administered into the CSF induce robust gene silencing throughout the central nervous system (CNS). Upon clearance from the CSF, they are mainly filtered by the kidneys and liver, with the most functionally significant accumulation occurring in the liver. siRNA- and miRNA-induced silencing can be blocked through substrate inhibition using single-stranded, stabilized oligonucleotides called antagomirs or anti-siRNAs. Using APOE as a model target, we show that undesired di-siRNA-induced silencing in the liver can be mitigated through administration of liver targeting GalNAc-conjugated anti-siRNAs, without impacting CNS activity. Blocking unwanted hepatic APOE silencing achieves fully CNS-selective silencing, essential for potential clinical translation. While we focus on CNS/liver selectivity, coadministration of differentially targeting siRNA and anti-siRNAs can be adapted as a strategy to achieve tissue selectivity in different organ combinations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA, 01605, USA.
- Department of Psychiatry, University of Massachusetts Medical School, Worcester, MA, 01605, USA.
- Department of Medicine, University of Massachusetts Medical School, Worcester, MA, 01605, USA.
ORCID-Profile: Chantal M Ferguson, Dimas Echeverria, Matthew Hassler, Julia Alterman, Vignesh Hariharan, Jonathan Watts, Anastasia Khvorova
Förderung
- Alzheimer's Drug Discovery Foundation
- NIA NIH HHS
- NIGMS NIH HHS
- NINDS NIH HHS
- NIH HHS
- National Institutes of Health
- National Institute on Aging
- National Institute of General Medical Sciences
Zitieren
APA
Ferguson, C. M., Godinho, B. M. D. C., Echeverria, D., Hassler, M., Vangjeli, L., Sousa, J., McHugh, N., Alterman, J., Hariharan, V., Krishnamurthy, P. M., Watts, J., Rogaev, E., & Khvorova, A. (2024). A combinatorial approach for achieving CNS-selective RNAi. Nucleic Acids Research. https://doi.org/10.1093/nar/gkae100
Vancouver
Ferguson CM, Godinho BMDC, Echeverria D, Hassler M, Vangjeli L, Sousa J, et al. A combinatorial approach for achieving CNS-selective RNAi. Nucleic Acids Research. 2024. doi:10.1093/nar/gkae100
BibTeX
@article{Ferguson2024,
author = {Ferguson, Chantal M and Godinho, Bruno M D C and Echeverria, Dimas and Hassler, Matthew and Vangjeli, Lorenc and Sousa, Jacquelyn and McHugh, Nicholas and Alterman, Julia and Hariharan, Vignesh and Krishnamurthy, Pranathi Meda and Watts, Jonathan and Rogaev, Eveny and Khvorova, Anastasia},
title = {A combinatorial approach for achieving CNS-selective RNAi},
journal = {Nucleic Acids Research},
year = {2024},
doi = {10.1093/nar/gkae100}
}
EUVIMED